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Abstract
Background: Osteoporosis mainly occurs in postmenopausal women, which is characterized by low bone mineral density
(BMD) due to unbalanced bone resorption by osteoclasts and formation by osteoblasts. Circulating monocytes play
important roles in osteoclastogenesis by acting as osteoclast precursors and secreting osteoclastogenic factors, such as IL-
1, IL-6 and TNF-a. MicroRNAs (miRNAs) have been implicated as important biomarkers in various diseases. The pre-
sent study aimed to find significant miRNA biomarkers in human circulating monocytes underlying postmenopausal
osteoporosis.
Methodology/Principal Findings: We used ABI TaqManH miRNA array followed by qRT-PCR validation in circulating
monocytes to identify miRNA biomarkers in 10 high and 10 low BMD postmenopausal Caucasian women. MiR-133a was
upregulated (P=0.007) in the low compared with the high BMD groups in the array analyses, which was also validated by
qRT-PCR (P=0.044). We performed bioinformatic target gene analysis and found three potential osteoclast-related target
genes, CXCL11, CXCR3 and SLC39A1. In addition, we performed Pearson correlation analyses between the expression levels
of miR-133a and the three potential target genes in the 20 postmenopausal women. We did find negative correlations
between miR-133a and all the three genes though not significant.
Conclusions/Significance: This is the first in vivo miRNA expression analysis in human circulating monocytes to identify
novel miRNA biomarkers underlying postmenopausal osteoporosis. Our results suggest that miR-133a in circulating
monocytes is a potential biomarker for postmenopausal osteoporosis.
Citation: Wang Y, Li L, Moore BT, Peng X-H, Fang X, et al. (2012) MiR-133a in Human Circulating Monocytes: A Potential Biomarker Associated with
Postmenopausal Osteoporosis. PLoS ONE 7(4): e34641. doi:10.1371/journal.pone.0034641
Editor: Qingyang Huang, Central China Normal University, China
Received February 7, 2012; Accepted March 2, 2012; Published April 10, 2012
Copyright:  2012 Wang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by grants from the State of Nebraska (LB692 and LB595) and the NIH (R01AR04054496-02S1). The funders had no role in
study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: pxiao@creighton.edu
Introduction
Tissue-specific expressed microRNAs (miRNAs) are short non-
coding RNA molecules that regulate gene expression, generally by
destabilizing mRNAs or suppressing translation. MiRNAs have
been identified as important biomarkers and regulators in various
human diseases such as cancer [1,2], diabetes [3,4] and
myocardial disease [5]. In the bone area, many miRNAs regulate
osteoblastogenesis [6–16]. However, very few miRNAs have been
related to osteoclastogenesis [17,18]. MiRNA miR-223 played an
essential role in osteoclastogenesis in a mouse osteoclast precursor
cell line [18]. MiR-146a inhibited osteoclastogenesis from human
circulating mononuclear cells [17].
Circulating monocytes are important cells that participate in
osteoclatogenesis by acting as osteoclast precursors [19–22] and
secreting osteoclastogenesis-related factors, such as IL-1 (interleu-
kin-1), IL-6 and TNF-a (tumor necrosis factor-alpha) [23–25]. In
addition, human studies have found associations of gene
expression levels in circulating monocytes and osteoporosis, such
as ANXA2 (annexin A2) [26], STAT1 (signal transducer and
activator of transcription 1) [27], CCR3 [chemokine (C-C motif)
receptor 3], HDC (histidine decarboxylase), and GCR (glucocor-
ticoid receptor) [28].
However, no study has been conducted to identify miRNA
biomarkers in circulating monocytes associated with human
osteoporosis in vivo. Our present study aimed to identify
differentially expressed miRNAs in circulating monocytes isolated
from postmenopausal Caucasian women with discordant bone
mineral density (BMD) using ABI miRNA array technology
followed by qRT-PCR (quantitative RT-PCR). We found the
significance of miR-133a in human circulating monocytes
associated with postmenopausal osteoporosis. Further bioinfor-
matic analysis of miR-133a identified its potential target genes that
may be important in osteoclastogenesis.
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Human subjects and characteristics
The study was approved by the Institutional Review Board at
Creighton University, and all the subjects signed informed-consent
documents before entering the project. All the subjects were
Caucasians of European origin recruited from the vicinity of
Creighton University in Omaha, NE. The exclusion criteria were
detailed in our previous mRNA expression profiling study on B
cells isolated from postmenopausal Caucasians for different BMD
status [29]. The information such as age, ethnicity, menstrual
status, medication history, and disease history was obtained via
questionnaire. We recruited 20 unrelated postmenopausal Cau-
casian women, 10 with high BMD (spine or hip Z-score.0.84)
and 10 with low BMD (spine or hip Z-score,20.84). The high
and low BMD groups are the top and bottom 20% BMD
distributions of the age-, sex- and ethnicity-matched population.
BMD (g/cm
2) for the lumbar spine (L1-4) and total hip (femoral
neck, trochanter, and intertrochanteric region) were measured by
Hologic 4500A dual energy X-ray absorptiometry (DXA) scanners
(Hologic Inc., Bedford, MA). The machine was calibrated daily.
The measurement precision as reflected by the coefficient of
variation (CV) was 0.9% and 1.4% for spine and hip BMD,
respectively. Postmenopausal status was defined as the date of the
last menses followed by at least 12 months of no menses. All the
study subjects were aged 57–68. The detailed characteristics of the
study subjects are summarized in Table 1.
As shown in Table 1, both hip and spine BMD were
significantly different between the high and low BMD groups.
For age, weight and height traits, only height showed marginal
difference between the two BMD groups. However, height only
demonstrated a very small effect on quantitative BMD variations
[30]. Moreover, in this study, BMD was classified as a quality trait
into two categories, the low and the high BMD. Therefore, the
effect of height on BMD can be ignored in this study.
Monocyte isolation
Blood mononuclear cells (MNCs) from 70 ml peripheral blood
from each study subject were separated by density gradients with
UNI-SEP tubes containing a solution of 5.6% polysucrose and
9.6% sodium metrizoate with a density of 1.077 g/ml (Novamed,
Jerusalem, Israel). Monocytes were isolated by a negative isolation
kit, DynabeadsH Untouched
TM Human Monocytes (Dynal
Biotech, Lake Success, NY, USA), which contains a cocktail of
CD2, CD7, CD16, CD19, CD56 and CD235a antibodies to
deplete T cells, B cells, natural killer cells, erythrocytes and
granulocytes, leaving monocytes naive and free of the surface-
bound antibody and beads. The purity of isolated monocytes was
assessed by flow cytometry with fluorescence labeled antibodies
CD19-PE and CD45-FITC (BD Biosciences, San Jose, CA USA),
and the average purity is about 85% with 3% deviation.
Total RNA extraction
The mirVana miRNA Isolation Kit (Ambion, Austin, Texas,
USA) was used to extract total RNA including miRNAs from each
cell sample following the manufacturer’s protocol. Total RNA
concentration and integrity were evaluated by an Agilent 2100
Bioanalyzer (Agilent, Palo Alto, CA, USA). Each RNA sample has
a high quality with an excellent integrity number .9.0.
MiRNA array procedures
We used TaqManH Human MicroRNA Array v1.0 (Applied
Biosystems, Foster City, CA, USA) to perform miRNA expression
profiling for each RNA sample. Each array covers 365 human
miRNAs and endogenous controls RNU48 and RNU44. First,
TaqMan miRNA Multiplex Reverse Transcription Kit (Applied
Biosystems) was used for the RT reaction. For each RNA sample,
the RT reaction was performed in a 63 ml reaction system
including 1.8 ml 100 mM dNTPs, 18 ml Reverse Transcriptase
(50 U/ml), 9 ml1 0 6RT Buffer, 1.13 ml RNase Inhibitor (20 U/
ml), 16 ml sample RNA, and 17.08 ml nuclease-free water. The
reaction conditions were as follows: 30 min at 16uC, 30 min at
42uC, and 5 min at 85uC. After that, we mixed 450 ml diluted RT
reaction product (diluted 62.5-fold) with 450 ml TaqMan Univer-
sal PCR Master Mix (ABI) and loaded 100 ml real-time PCR
reaction mix into each port of the array card (8 ports/card). The
real-time qRT-PCR for each array was carried out on an Applied
BioSystems 7900HT Fast Real-time PCR System with the
following reaction conditions: 2 min at 50uC, 10 min at 95uC,
40 cycles of 15 sec at 95uC plus 1 min at 60uC. For each array
card, there was only one probe for each target miRNA.
In the miRNA array data analysis, the raw expression level was
determined by the cycle number at which the reaction crossed a
predetermined cycle threshold (CT) as identified for each miRNA
probe. The relative quantity (RQ) of each miRNA for each sample
is determined by 2
2DDCT, where DCT=(CTTarget miRNA2
CTendogenous control RNU48) and DDCT=(DCT2average DCT of
all the samples). The RQ data were used for student’s t test to
identify differentially expressed miRNAs between the high and the
low BMD groups.
qRT-PCR for miRNAs
To correct for the multiple-testing comparison and eliminate
false positive results in the miRNA array analysis, we conducted
qRT-PCR among the same 20 RNA samples to further validate
the identified significant miRNAs in the array analysis. Two-step
qRT-PCR was used to confirm the differentially expressed
miRNAs. The first step is RT of cDNA and the second step is
real-time quantitative PCR. All the reagents are provided by
Applied Biosystems. The RT reaction was performed in a 15 ml
volume, containing 1.5 ml Taqman RT Buffer (106), 0.15 ml
100 mM dNTPs (100 mM), 1.0 ml Reverse Transcriptase, 0.19 ml
RNase inhibitor (20 U/ml), 3.0 ml specific miRNA primer, 100 ng
total RNA, and nuclease-free water to make the final volume
15 ml. The real-time quantitative PCR was performed in a 20 ml
reaction volume using standard protocols on the Applied
Biosystems 7900HT System. Briefly, 2.5 ml cDNA was mixed
with 10.0 ml TaqMan universal PCR master mix (26), 1.0 ml
TaqMan miRNA assay and 6.5 ml nuclease-free water. The
reaction conditions were the same as the above real-time PCR in
the array experiments. For each RNA sample, the target miRNA
Table 1. Characteristics of the study subjects.
Traits
High BMD
(n=10)
Low BMD
(n=10) P Value
Age (yrs) 63.663.2 61.662.6 0.15
Height (cm) 159.263.2 163.664.7 0.03
Weight (kg) 76.767.9 72.9617.6 0.55
Spine BMD (g/cm
2)1 . 1 2 8 60.058 0.82660.069 ,0.001
Spine Z-Score 2.2460.59 20.6360.64 ,0.001
Hip BMD (g/cm
2)1 . 0 5 7 60.101 0.72560.045 ,0.001
Hip Z-Score 1.9460.99 21.0460.45 ,0.001
Note: The data are mean 6SD.
doi:10.1371/journal.pone.0034641.t001
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The RQ of each miRNA for each sample is determined by
2
2DDCT, where DCT=(average of triplicate CTTarget miRNA2
average of triplicate CTendogenous control RNU48) and
DDCT=(DCT2average DCT of all the samples). The RQ data
were used for student’s t test between the two groups.
Target gene prediction and verification
We conducted bioinformatic sequence analysis of each
significant miRNA to identify potential target genes [31]. MiRNAs
normally repress gene expression by base pairing at complemen-
tarity sites mainly but not exclusively in the 39-untraslated region
(39-UTR) of the target mRNAs [32,33]. The currently available
miRNA target gene databases are all limited in the 39-UTR
analyses. We used both miRDB (http://www.miRDB.org/) and
TargetScan (http://www.targetscan.org/) databases to predict
target genes by searching for the presence of conserved 8-mer and
7-mer sites in their 39-UTRs that match the seed region of each
significant miRNA [34]. In addition, we also conducted qRT-PCR
for the potential target genes of the significant miRNA among the
same 20 RNA samples. Similar to miRNA qRT-PCR, the mRNA
qRT-PCR was also composed of RT and real-time qPCR. The
first step is RT of cDNA and the second step is real-time
quantitative PCR. The RT and qPCR were in 100 ml and 25 ml
volumes, respectively, following the company’s standard protocols
(Applied Biosystems). For each RNA sample, the target mRNA
and internal control b-actin were run as triplicates in the same
plate. We used the same calculation for RQ 2
2DDCT as we did for
miRNA qRT-PCR and performed student’s t test between the two
groups.
Results
MiRNA array analyses
Among the 365 miRNAs in the array, the expression of many
miRNAs were missing among the 20 study samples, probably due
to tissue-specific expression or extremely low expression. To
obtain enough power, we selected miRNAs that were expressed
in at least 5 samples in each BMD group for the analyses.
According to this criterion, 156 qualified miRNAs (Table S1)
were subject to the statistical analyses and two miRNAs, miR-
133a and miR-382, showed significant upregulation in the low
BMD group compared with the high BMD group (Figure 1).
Specifically, miR-133a displayed a fold change of 6.48 between
the low and high BMD groups as mean 6 SD (4.2162.15 vs.
0.6560.75, P=0.007), and miR-382 showed a fold change of
3.65 between the low and high BMD groups (2.7462.18 vs.
0.7560.63, P=0.027).
qRT-PCR for miRNAs
We further performed qRT-PCR to validate the differential
expression of miR-133a and miR-382. However, only the
upregulation of miR-133a in monocytes in the low vs. the high
BMD group (2.2162.08 vs. 0.7660.37) was validated by qRT-
PCR (P=0.044). The difference in expression of miR-382 in
monocytes in the low vs. the high BMD group (6.5662.84 vs.
7.9369.73) was not significant (P=0.67) (Figure 2).
Target gene prediction and verification
Our bioinformatic sequence analyses identified 226 potential
target genes that are overlapped in both miRDB and TargetScan
databases. By searching relevant references for all the 226 genes,
we found that three of them are related to osteoclastogenesis,
CXCL11 [chemokine (C-X-C motif) ligand 11], CXCR3
[chemokine (C-X-C motif) receptor 3], and SLC39A1 [solute
carrier family (zinc transporter), member 1]. Table 2 demon-
strates the specific putative binding sites of miR-133a in the 39
UTRs of the three genes. We conducted qRT-PCR analyses for
all the three genes among the same 20 study samples and did not
find significant differential expression. In addition, we performed
correlation analysis of the expression levels of miR-133a and
each gene. All three genes did demonstrate negative correlation
with miR-133a, although they were not significant (P.0.05)
(Table 3).
Figure 1. Expression levels (2
2DDCT) of significant miRNAs
measured by array analysis in circulating monocytes in the low
and high BMD groups (**: P,0.01; *: P,0.05).
doi:10.1371/journal.pone.0034641.g001
Figure 2. Expression levels (2
2DDCT) of miR-133a and miR-382
measured by qRT-PCR analysis in circulating monocytes in the
low and high BMD groups (*: P,0.05).
doi:10.1371/journal.pone.0034641.g002
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In this study, we aimed to identify important miRNAs in human
circulating monocytes associated with discordant BMD status in
postmenopausal Caucasian women. We found significant upregu-
lation of miR-133a in the low BMD group in both the array and
the qRT-PCR analyses.
Human mature miR-133a is encoded by two genes: MIR133A1
for miR-133a1 at 18q11.2 (194,036,59–194,077,46 bp) and
MIR133A2 for miR-133a2 at 20q13.33 (611,601,19–
611,642,20 bp). Both genes encode different pre-mature miRNAs
but generate the same mature miR-133a sequence. Interestingly,
human genetic studies also found the association of 18q11.2 to
osteoporosis-related traits [35] and linkage of 20q13 to bone
phenotypes [36–38]. In humans, there are two types of miR-133
miRNA isoforms, miR-133a and miR-133b, with one base
difference (g-a) in the last nucleotide at the 39 end (miRBase:
http://www.mirbase.org/). The ABI miRNA array used in this
study includes both miR-133a and miR-133b probes. Interesting-
ly, miR-133b is marginally unregulated in the low vs. the high
BMD groups (1.5160.67 vs. 0.9560.63, P=0.08). In addition, we
detected miR-133a expression levels in circulating B cells from the
same 20 high or low BMD postmenopausal women. Circulating B
cells were isolated by DynabeadsH CD19 (Pan B) (Dynal Biotech).
However, miR-133a was not differentially expressed in B cells
between the high and the low BMD groups (P=0.49). Therefore,
miR-133a is most likely to be a monocyte specific biomarker
underlying postmenopausal osteoporosis.
Many studies demonstrated that miR-133 and 133a are
important in the development of muscle, such as skeletal muscle
[39–43], and heart/cardiovascular muscle [44–47]. In bone,
particularly, miR-133 and 133a have been found to regulate
osteoblastogenesis by targeting and regulating Runx2 expression
[6,48]. A recent study also demonstrated that miR-133a was
upregulated in osteoblast-like periodontal ligament stem cells
treated with ibandronate, a nitrogen-containing bisphosphonate
that inhibits bone resorption and is widely used to treat
osteoporosis [49]. However, our study for the first time showed
the association of miR-133a expression levels in circulating
monocytes, the osteoclast precursors, with postmenopausal
osteoporosis.
To further predict what genes are targeted and regulated by
miR-133a in monocytes in bone metabolism, we used two miRNA
target gene predicting databases (miRDB and TargetScan) [50–
55]. Our bioinformatic sequence analyses and reference searching
identified three potential target genes of miR-133a related to the
inhibition of osteoclastogenesis, which are CXCL11, CXCR3, and
SLC39A1 (Table 2). CXCL11 is a small cytokine of the CXC
chemokine family. CXCL11 has been shown to inhibit osteoclast
differentiation of CD14+ monocytes [56]. CXCR3 is a Gai
protein-coupled receptor in the CXC chemokine receptor family.
CXCR3 expression significantly decreased during osteoclast
differentiation [57]. The SLC39A1 gene encodes zinc transporter
1 (ZIP1). Zinc deficiency has been correlated with reduction of
bone growth and development of osteoporosis [58,59]. SLC39A1
has been detected in osteoclasts and inhibited osteoclastogenesis
and osteoclast function through zinc uptake [60].
All three genes did show negative correlation with miR-133a,
though not significant (Table 3). Since one single miRNA normally
regulates the expression of hundreds of genes, the regulatory effect
of each gene may be small. Osteoporosis is a complex disease and
regulated by multiple genes [61]. To investigate the combined
effects, we also utilized a principle component analysis (PCA) to
analyze the qRT-PCR observations from all three potential target
genes. The PCA was performed using the correlation matrix. The
analysis reduced the original data into two principle components
(PC) that account for 58.17% and 32.78% of the total variance,
respectively. A plot of the second PC against the first PC in the 10
high and 10 low BMD subjects is shown in Figure 3. We can see
that both PCs are above the average levels in 6 out of 10 high
BMD subjects and below the average levels in 7 out of 10 low
BMD subjects, which means that the three genes are systematically
upregulated in the high vs. low BMD groups. This result is
Table 2. Putative binding sites of miR-133a in predicted target genes in humans.
Target Gene
39 UTR
Position
Consequential Pairing
Target gene binding region (top) and miR-133a sequence (bottom)
59...AAAGGUGGGUGAAAGGACCAAA...
CXCL11 171–177 |||||||
39 GUCGACCAACUUCCCCUGGUUU
59...AAACAAGAUCGUCAGGACCAAA...
CXCR3 444–450 |||||||
39 GUCGACCAACUUCCCCUGGUUU
59...AAGGGAAAUACUGAGGACCAAA...
SLC39A1 107–113 |||||||
39 GUCGACCAACUUCCCCUGGUUU
doi:10.1371/journal.pone.0034641.t002
Table 3. Correlation of expression levels (2
2DDCT) of miR-133a
with those of three potential target genes and the ratio of
expression levels of each gene in the high and low BMD
groups, as measured by qRT-PCR.
Gene Fold Change (H/L) Correlation Coefficient P Value
CXCL11 2.70 20.04 0.88
CXCR3 3.02 20.22 0.36
SLC39A1 1.33 20.02 0.94
Note: H/L: high/low BMD groups.
doi:10.1371/journal.pone.0034641.t003
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the high vs. low BMD groups.
There are some limitations for this study. In the miRNA array
data, we performed the statistical tests for the 156 miRNAs
according to expression data available in at least five samples in
each group, and used raw P values but not adjusted P values for
multiple tests. Actually, we did not find significant miRNAs after
multiple testing adjustments by Bonferroni. However, the
significant qRT-PCR P value confirmed the differential expression
of miR-133a in the array analyses. The qRT-PCR validation
largely solved the multiple testing problem. The sample size of 20
is relatively small. However, it is enough for an initial biomarker
screening according to our previous [29,62] and other [63,64]
gene expression profiling studies. Moreover, we are also planning
to validate the miR-133a biomarker in a larger independent
population. We did not find significant correlations of miR-133a
and selected potential target genes. First, it may be due to the
limited sample size to get enough power to detect the significant
correlation. Second, many miRNAs inhibit gene expression by
only suppressing protein translation instead of mRNA degradation
[32,33]. Third, there may be other unknown target genes of miR-
133a in circulating monocytes that affect osteoclastogenesis.
Therefore, we will test the current and potential novel target
gene expression and correlation with miR-133a in a bigger
population at both mRNA and protein levels in the future.
In summary, this is an initial miRNA expression study to
indentify miRNA biomarkers in human circulating monocytes
underlying postmenopausal osteoporosis. Our study suggested that
miR-133a is a potential miRNA biomarker and/or regulatory
element in circulating monocytes for postmenopausal osteoporosis.
Supporting Information
Table S1 MiRNA array results of 156 miRNAs that were
expressed in at least 5 samples in each BMD group. *: the ratio of
the mean expression values between the low and high BMD
groups.
(DOC)
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